NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.
Read More
Maxigesic Oral Liquid – a non-opioid analgesic developed for children – achieves first approval in Europe to set up the first global launch and a pathway for further registrations and launches.
Read More
AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has licensed Maxigesic IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extending the medicine’s addressable market in Latin America and the Caribbean to 17 countries.
Read More
AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has received a US Food and Drug Administration (FDA) complete response letter (CRL).
Read More
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has today appointed Anita Baldauf as a non-executive director.
Read More
Agreement covers pharmaceutical-grade medicinal cannabis ingredients for products initially targeted for Australia and New Zealand
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed exclusive Maxigesic IV® distribution and supply agreements for the UK and Hong Kong, with the company targeting sales of the medicine in these territories in 2022.
Read More
ASX-listed RooLife (ASX:RLG) and ASX and NZX-listed AFT Pharmaceuticals (ASX:AFP, NZX:AFT) have officially launched the New Zealand branded online health and pharmacy store in China “Kiwi Health”
Read More
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Thursday November 19 2020 its half year interim results for the period ended September 30 2020. The release will be issued at around 09:00.
Read More
Notice is hereby given that the adjourned Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be convened and held on a fully virtual basis on Tuesday, 8 September 2020 commencing at 10.30am (New Zealand time) to transact the business set out in the Notice of Annual Meeting of Shareholders 2020 dated 15 July 2020 (Original AGM Notice).
Read More
AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) advises that the Annual Meeting of shareholders of AFT scheduled for 10.30am (NZ time) today will be adjourned to a time and date to be advised. This follows the Government’s announcement that the Auckland Region will move to COVID-19 alert level 3 today, which means that shareholders should stay home and refrain from attending the meeting.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed an exclusive Maxigesic IV® licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic, Hungary, Romania and Slovakia, countries with a combined population of more than 53 million*.
Read More
AFT Pharmaceuticals (NZX:AFT, ASX:AFT) today welcomes Medsafe’s announcement that all codeine and codeine-containing medicines will become prescription only from 5 November 2020.
Read More
Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (*AFT or the Company*) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on *Wednesday, 12 August 2020 commencing at 10.30am* (New Zealand time).
Read More
RooLife partners with ASX & NZX-listed AFT Pharmaceuticals (ASX:AFP, NZX:AFT) to deliver New Zealand branded online health & pharmacy store in China
Read More